Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Phase 2 Completed 55 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.

Timeline

Start: 2010-06
Primary completion: 2014-02
Completion: 2014-02

Publications

Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 3;122(14):2331-7. doi: 10.1182/blood-2013-01-481325. Epub 2013 Aug 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Panobinostat	Small molecule	20 mg	Oral
Background	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	20 mg	Oral

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications